94406 ⎘
Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms; Oxygen or sulfur atoms; One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
SMALL MOLECULE INHIBITORS OF PR3 AND HNE AND USES THEREOF
#2COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS
#3Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
#4Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
#5SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF AUTOIMMUNE, INFLAMMATION OR INFECTION RELATED DISORDERS
#6Necrosis inhibitors
#7Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
#8Necrosis inhibitors
#9Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
#10Cyclic N-carboxamide compounds useful as herbicides
#11N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES
#12ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
#13Compounds for the treatment of paramyxovirus viral infections
#14Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
#15N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES
#16Compounds for the treatment of paramoxyvirus viral infections
#17Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
#18N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES
#19CETP INHIBITORS
#20COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
#21Latent acids and their use
#22N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
#231,3 imidazolidine derivatives and their use in the production of carbapenem
#24Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
#25CETP inhibitors
#26Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
#27Imidazolidine derivatives
#28VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
#29Kv1.5 potassium channel inhibitors
#30CHEMICAL COMPOUNDS
#31Sulphonamide Derivatives
#32Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
#33Process for the controlled increase in the molecular weight of polyethylenes
#34Cetp Inhibitors
#35Kv1.5 potassium channel inhibitors
#36Process for the controlled increase in the molecular weight of polyethylenes
#37Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
#38CETP inhibitors
#39Vanilloid receptor ligands and their use in treatments
#40Vanilloid receptor ligands and their use in treatments
#41Vanilloid receptor ligands and their use in treatments
#42Vanilloid receptor ligands and their use in treatments
#43Vanilloid receptor ligands and their use in treatments
#44Vanilloid receptor ligands and their use in treatments
#45Dipeptidyl peptidase-IV inhibitors
#46Vanilloid receptor ligands and their use in treatments
#47Tetrahydroisoquinolnyl sulfamic acids
#48Novel heterocyclic compound and anti-inflamatory agent